What is GRCE's dilution risk score?

GRCE has a latest available DilutionScore record of 52/100, categorized as high dilution risk by the DilutionWatch scoring model. DilutionWatch displays SEC filing and dilution indicators for GRCE, including shelf registrations, ATM offerings, warrant exercises, PIPE deals, and reverse split signals when detected in source data.

What SEC filings does DilutionWatch track for GRCE?

DilutionWatch tracks 25 SEC filing types for GRCE including S-3 shelf registrations, 424B prospectuses (ATM offerings), S-1 registration statements, 8-K material events, warrant exercise notices, convertible note agreements, and Form 4 insider transactions. Alerts are delivered via email within minutes of a filing appearing on EDGAR.

How does stock dilution affect GRCE shareholders?

Stock dilution occurs when a company issues new shares, reducing the ownership percentage of existing shareholders. For GRCE, common dilution events include at-the-market (ATM) stock offerings, shelf registration drawdowns, warrant exercises, and convertible note conversions. Each event increases the share count and can pressure the stock price lower.

Is DilutionWatch free for GRCE tracking?

DilutionWatch provides a free tier that shows DilutionScores and basic filing history for GRCE. Premium plans ($19.95/month Basic, $39.95/month Premium) unlock real-time email alerts, the full Pulse™ feed, advanced dilution forecasts, and access to all 10,000+ tracked tickers.

GRCE Dilution Risk Score: 52/100 (HIGH)

Score Breakdown

📋 Offering Ability

52

💰 Cash Runway

65

📊 Float Risk

30

⚠️ Warrant Exposure

40

🔄 Convertible Debt

40

Dilution Forecast

☀️

Clear

No significant dilution signals

model est. 7%

💰 Capital Raise model 15%

• Under 12 months cash (11mo)

🔔 Track GRCE — Get forecast alerts →

Market Data

Market Cap$39.77M

Shares Outstanding21.04M

Float12.79M

Cash$13.77M

DebtN/A

Short InterestN/A

Institutional Holdings

QoQ: ↓ 12.0% shares (2026Q1 vs prior)

35 institutional holders · 4.81M shares

#1 Cerity Partners LLC 849.1K shares

#2 VANGUARD CAPITAL MANAGEMENT LLC 803.3K shares

#3 Eversept Partners, LP 756.6K shares

+ 17 more holders Sign up free to view →

Institutional holder totals are aggregated from ownership filings and may use a different share basis or reporting date than public float. They are not a reconciliation against tradeable float.

Short Interest

Short Interest1.59M

Days to Cover5.7

% of Float12.4%

FINRA data as of Jul 31, 2026

Insider Buy/Sell Ratio

Recent SEC Activity

xbrl XBRL WARRANT 2026-03-31

4 INSIDER TRANSACTION 2026-08-19

SC 13G/A BENEFICIAL OWNERSHIP 2026-08-14

SC 13G BENEFICIAL OWNERSHIP 2026-08-07

8-K 8K EVENT 2026-08-06

Full SEC filing analysis available with free account →

Recent News

Grace Therapeutics Files for Resale of Up to 4.8 Million Shares MT Newswires · Aug 24

Grace Therapeutics Announces Receipt of Type A Meeting Minutes from U.S. Food an GlobeNewswire · Jul 28

Grace Therapeutics Announces 2026 Fiscal Year-End Financial Results, Provides Bu GlobeNewswire · Jun 18

Factual GRCE Dilution Snapshot

Grace Therapeutics, Inc. (GRCE) has a DilutionScore of 52/100, rated High dilution risk. Score date: August 28, 2026.

Recent SEC activity tracked for GRCE: 4 on 2026-08-19; SC 13G/A on 2026-08-14; SC 13G on 2026-08-07.

This automatically generated snapshot is assembled from stored DilutionWatch data fields and may contain data-source errors or omissions. It is not financial advice, not investment research, and not a recommendation. Do your own research and review the full disclaimer and terms of service.